|
|
Post by careful2invest on Sept 25, 2017 8:44:02 GMT -5
Mike mentined Ray Urbanski as part of the current Mannkind staff in todays conference 9/25/17.
Last conference, he said that Ray had moved on from Mannkind due to Rays history in Oncology.
Any insight?
GLTA!
|
|
|
|
Post by casualinvestor on Sept 25, 2017 8:46:01 GMT -5
|
|
|
|
Post by #NoMoreNeedles on Sept 25, 2017 8:46:15 GMT -5
September 29 last day.
|
|
|
|
Post by careful2invest on Sept 25, 2017 8:55:12 GMT -5
That thread was locked with the verdict that Ray was gone. Mike would not introduce him in a current presentation if he were gone now, would he? |
|
|
|
Post by mnkdnewbie on Sept 29, 2017 19:31:13 GMT -5
Announce new cmo and label change or announce new cmo to spearhead a new label change application?
|
|
|
|
Post by sportsrancho on Oct 1, 2017 8:28:33 GMT -5
|
|
|
|
Post by peppy on Oct 1, 2017 8:34:55 GMT -5
Its lead drug candidate, OXS-1550 (DT2219ARL) is a novel bispecific scFv recombinant fusion protein-drug conjugate composed of the variable regions of the heavy and light chains of anti-CD19 and anti-CD22 antibodies and a diphtheria toxin as its cytotoxic drug payload. OXS-1550 targets and binds to cancer cells expressing the CD19 receptor or CD22 receptor or both receptors. When OXS-1550 binds to cancer cells, they internalize the drug and are killed due to the cytotoxic payload. OXS-1550 has demonstrated encouraging results in early human clinical trials in patients with relapsed/refractory B-cell lymphoma or leukemia. OXS-3550 TriKE technology was developed by researchers at the University of Minnesota Masonic Cancer Center. As demonstrated in non-clinical models, this targeted immunotherapy directs NK cells to kill cancer cells while diminishing the drug-related toxicity and is anticipated to be to NK cells what CAR-T is to T-cells. Additionally, GT Biopharma is focused on acquiring or discovering and patenting late-stage, de-risked, and close-to-market improved treatments for Central Nervous System disease and shepherding the products through the FDA approval process to the NDA. Its CNS products currently include treatment for neuropathic pain, refractory epilepsies, the symptoms of myasthenia gravis, and motion sickness. |
|
|
|
Post by mnkdfann on Oct 1, 2017 8:57:00 GMT -5
That thread was locked with the verdict that Ray was gone. Mike would not introduce him in a current presentation if he were gone now, would he? I think the last post was meant to be read in a future perfect tense sort of way. Ray's resignation was handed in at the time, and his departure date was known. |
|
|
|
Post by careful2invest on Oct 1, 2017 9:59:58 GMT -5
That thread was locked with the verdict that Ray was gone. Mike would not introduce him in a current presentation if he were gone now, would he? I think the last post was meant to be read in a future perfect tense sort of way. Ray's resignation was handed in at the time, and his departure date was known. I found that out since my last post on this thread, but thank you for your response. |
|
|
|
Post by lakers on Oct 1, 2017 11:32:49 GMT -5
www.baystreet.ca/viewarticle.aspx?id=476418Baystreet Staff - Wednesday, September 27, 2017 GT Biopharma, Inc. Announces Corporate Update Conference Call with CEO Dr. Kathleen Clarence-Smith, CMO Dr. Raymond Urbanski and Chairman Anthony Cataldo [ACCESSWIRE] WASHINGTON, DC / ACCESSWIRE / September 27, 2017 / GT Biopharma Inc. (OTCQB: GTBP), a targeted immunotherapies company with close to market treatments for Central Nervous System (CNS) diseases (neurology and pain), will hold a conference call, hosted by www.biotechstocks.com, to discuss advancements made with the targeted immunotherapies currently in FDA clinical trials and its newly acquired CNS drugs. The call will start promptly at 4:15 pm EST on Monday, October 2, 2017. About GT Biopharma, Inc.: GT Biopharma is a pharmaceutical company developing innovative drugs focused on the treatment of cancer and other unmet medical needs. Its lead drug candidate, OXS-1550 (DT2219ARL) is a novel bispecific scFv recombinant fusion protein-drug conjugate composed of the variable regions of the heavy and light chains of anti-CD19 and anti-CD22 antibodies and a diphtheria toxin as its cytotoxic drug payload. OXS-1550 targets and binds to cancer cells expressing the CD19 receptor or CD22 receptor or both receptors. When OXS-1550 binds to cancer cells, they internalize the drug and are killed due to the cytotoxic payload. OXS-1550 has demonstrated encouraging results in early human clinical trials in patients with relapsed/refractory B-cell lymphoma or leukemia. OXS-3550 TriKE technology was developed by researchers at the University of Minnesota Masonic Cancer Center. As demonstrated in non-clinical models, this targeted immunotherapy directs NK cells to kill cancer cells while diminishing the drug-related toxicity and is anticipated to be to NK cells what CAR-T is to T-cells. Additionally, GT Biopharma is focused on acquiring or discovering and patenting late-stage, de-risked, and close-to-market improved treatments for Central Nervous System disease and shepherding the products through the FDA approval process to the NDA. Its CNS products currently include treatment for neuropathic pain, refractory epilepsies, the symptoms of myasthenia gravis, and motion sickness. [CNS, pain, epilepsies are the same fields targeted by RLS by different method. Could RLS be merged with Mnkd? Could Andrea Leone-Bay come back to Mnkd as CMO? Mike mentioned RLS as second pipeline. RLS failed applying for the company name several times. RLS backers are deep pocket. They can pump more money into the combined co. RLS needs the Danbury plant, TS. RLS's backers would acquire the plant, TS if needed. They have vested interest to prop up Mnkd. I would not be surprised if recap includes RLS's backers.]
|
|
|
|
Post by babaoriley on Oct 1, 2017 11:42:18 GMT -5
C'mon, "Ray Urbanski" is a very common name!!
|
|
|
|
Post by kc on Oct 1, 2017 11:44:39 GMT -5
|
|
|
|
Post by lakers on Oct 1, 2017 11:53:23 GMT -5
Not after his biggest contribution was Tresprotinil pre-NDA, PDUFA. He extended his stay until the pivotal 9/29/17. Bravo Ray! Welcome back the old pro Andrea ?? |
|
|
|
Post by kc on Oct 1, 2017 11:59:35 GMT -5
Will Andrea be returning? Is her husband still with MannKind?
|
|
|
|
Post by boytroy88 on Oct 1, 2017 15:12:41 GMT -5
Anyone notice the guest relations name -Stuart Pfeifer....hmmm...lol
|
|
